Revance Therapeutics, Inc. (NASDAQ:RVNC) Given Consensus Rating of “Hold” by Analysts

Revance Therapeutics, Inc. (NASDAQ:RVNC) has earned a consensus rating of “Hold” from the nine brokerages that are currently covering the stock, MarketBeat Ratings reports. Eight research analysts have rated the stock with a hold recommendation and one has assigned a buy recommendation to the company. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $8.39.

A number of equities research analysts have weighed in on RVNC shares. Mizuho cut their price target on shares of Revance Therapeutics from $6.66 to $3.10 and set a “neutral” rating for the company in a report on Tuesday, December 10th. Barclays cut their price target on shares of Revance Therapeutics from $7.00 to $3.00 and set an “equal weight” rating for the company in a report on Monday, December 23rd. Needham & Company LLC reissued a “hold” rating on shares of Revance Therapeutics in a report on Friday, January 17th. Finally, StockNews.com assumed coverage on shares of Revance Therapeutics in a research note on Tuesday, March 18th. They set a “hold” rating for the company.

Institutional Trading of Revance Therapeutics

A number of hedge funds have recently made changes to their positions in the stock. Beryl Capital Management LLC acquired a new position in Revance Therapeutics in the fourth quarter worth approximately $18,042,000. Alpine Associates Management Inc. acquired a new position in Revance Therapeutics in the third quarter worth approximately $21,605,000. Alliancebernstein L.P. increased its holdings in Revance Therapeutics by 7.3% in the fourth quarter. Alliancebernstein L.P. now owns 3,497,112 shares of the biopharmaceutical company’s stock worth $10,631,000 after buying an additional 236,641 shares during the last quarter. Magnetar Financial LLC increased its holdings in Revance Therapeutics by 2.2% in the fourth quarter. Magnetar Financial LLC now owns 2,556,345 shares of the biopharmaceutical company’s stock worth $7,771,000 after buying an additional 56,174 shares during the last quarter. Finally, State Street Corp grew its holdings in Revance Therapeutics by 6.6% during the third quarter. State Street Corp now owns 2,433,963 shares of the biopharmaceutical company’s stock valued at $12,632,000 after purchasing an additional 150,323 shares during the last quarter. 97.70% of the stock is owned by hedge funds and other institutional investors.

Revance Therapeutics Stock Performance

Shares of NASDAQ RVNC opened at $3.65 on Monday. Revance Therapeutics has a twelve month low of $2.30 and a twelve month high of $6.65. The company has a market capitalization of $381.02 million, a price-to-earnings ratio of -1.89 and a beta of 0.90. The firm has a 50-day moving average of $3.62 and a two-hundred day moving average of $4.23.

About Revance Therapeutics

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company’s lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.